Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine ...

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare ...

Reported positive YTD 2024 Adjusted EBITDA of $1.4 millionCompany expects Q4 2024 Net Revenue in the range of $37 million - $43 millionZYNRELEF® (bupivacaine and meloxicam) extended-release solution ...

Bupivacaine (brand name Marcaine) and lidocaine (brand name Xylocaine) are common local anesthetics. They can numb parts of ...

ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date ...

PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.

Participants can use guest dial-in numbers above to reach an operator or they can click the Call meTM link for instant telephone access to the event (dial-out). The Call meTM link will be made active ...

Pacira ended the third quarter of 2024 with cash, cash equivalents and available-for-sale investments ("cash”) of $453.8 ...

Congress passed the NOPAIN Act as part of the Consolidated Appropriation Act of 2023 to provide better patient access to ...

The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

In 2015 Siddiqui was struck off the General Medical Council Register after a panel of the Medical Practitioners Tribunal Service found him guilty failures in performing non-therapeutic male ...

Siddiqui is due to be sentenced on 14 January 2025 at Southwark Crown Court. Anja Hohmeyer of the Crown Prosecution Service ...